510(k) · Cleared
Recalled · Class II · 2022Etest Ceftazidime/Avibactam (CZA) (0.016 - 256 ug/mL)
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
bioMerieux, Inc. · JWY Manual Antimicrobial Susceptibility Test Systems
Cleared on Sep 15, 2017 as substantially equivalent to K170670 (bioMerieux, Inc., 2017) after a 60-day review. Its family tree reaches back 4 generations to 2010. 2 later devices descend from it. It has been recalled once.
- Decided
- Sep 15, 2017
- Review
- 60 days
- Class
- Class II
- Product code
- JWY
- Recalls
- 1
- Predicates
- 1
Its longest line of descent runs back 4 generations to K102668 (2010). 2 later devices descend from it, 2 citing it directly.
- Root · 4 generations backK102668 Etest Tobramycin 0.016-256 UG/ML and 0.064-1024 UG/MLBiomerieux · 2010 · Recalled
- 3 generations backK121002 Etest CeftarolinebioMerieux, Inc. · 2012 · Recalled
- 2 generations backK151873 Etest Ceftaroline (0.002 - 32ug/ml)Biomerieux S.A. · 2015
- 1 generation backK170670 Etest Ceftolozane/ Tazobactam (0.016-256 ug/ml)bioMerieux, Inc. · 2017 · Recalled
- This deviceK172150 Etest Ceftazidime/Avibactam (CZA) (0.016 - 256 ug/mL)bioMerieux, Inc. · 2017
- Descendant · cites it directly · 0 of its ownK250856 ETEST Aztreonam/Avibactam (AZA) (0.016/4-256/4 µg/mL)Biomérieux · 2025
- Descendant · cites it directly · 0 of its ownK190154 ETEST Piperacillin/Tazobactam (P/T) (0.016/4-256/4 ug/mL)Biomerieux S.A. · 2019
Most influential descendants
Showing 2 of 2 · See allView FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −4 | K102668 | Etest Tobramycin 0.016-256 UG/ML and 0.064-1024 UG/ML | Biomerieux | 2010 | 2 |
| −3 | K121002 | Etest Ceftaroline | bioMerieux, Inc. | 2012 | 5 |
| −2 | K151873 | Etest Ceftaroline (0.002 - 32ug/ml) | Biomerieux S.A. | 2015 | — |
| −1 | K170670 | Etest Ceftolozane/ Tazobactam (0.016-256 ug/ml) | bioMerieux, Inc. | 2017 | 1 |
| 0 (this device) | K172150 | Etest Ceftazidime/Avibactam (CZA) (0.016 - 256 ug/mL) | bioMerieux, Inc. | 2017 | — |
| +1 | K250856 | ETEST Aztreonam/Avibactam (AZA) (0.016/4-256/4 µg/mL) | Biomérieux | 2025 | — |
| +1 | K190154 | ETEST Piperacillin/Tazobactam (P/T) (0.016/4-256/4 ug/mL) | Biomerieux S.A. | 2019 | — |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2019 | 1 | 0 |
| 2025 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in JWY? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new JWY device
- #1 K260447 ETEST Gepotidacin (GEP) (0.016-256 µg/mL)score 12.7 · 6 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K170670 | Etest Ceftolozane/ Tazobactam (0.016-256 ug/ml)Summary page 5…st® Ceftazidime/Avibactam; Etest® CZA C. Predicate Device: Etest® Ceftolozane/Tazobactam (0.016-256 μg/ml) (K170670) D. Device Description: Etest® is a thin, inert and non-porous plastic strip carrying on one side (A) the MIC reading scale in… | 2017 |
What descends from it? (2)
2 later devices cite it directly; ranked here by how many devices descend from each in turn.
Has anything in its family been recalled? (0 Class I)
Recalls of this device
| Date | Class | Recall | Root cause | Reason |
|---|---|---|---|---|
| Nov 9, 2022 | Class II | Z-0846-2023 | Storage | As the temperature and time out of range was exceeded, product performances cannot be guaranteed |
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 7 years and passes through 3 companies; a new generation was cleared every 1.9 years on median.
- 3 of the 4 ancestors have a recall of any class.
- Of its descendants, K250856 (Biomérieux, 2025) has gone furthest, with 0 descendants of its own.
How does its category compare?
All JWY devicesJWY Manual Antimicrobial Susceptibility Test Systems: FDA decisions, review times, recalls and adverse event reports over 20 years. 2017, this device’s year, is highlighted.
FDA decisions per year · JWY
14in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · JWY
106in 2025
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · JWY
31in 2022
Class I (13 since 2007) Class II/III not classified
Adverse event reports per year · JWY
1in 2024
MAUDE reports naming product code JWY, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 0 |
| 2008 | 6 | 85 | 1 | 1 |
| 2009 | 2 | — | 0 | 1 |
| 2010 | 4 | 73 | 0 | 0 |
| 2011 | 4 | 125 | 3 | 0 |
| 2012 | 1 | — | 0 | 0 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 6 | 106 | 5 | 4 |
| 2015 | 9 | 90 | 6 (4) | 11 |
| 2016 | 4 | 88 | 0 | 20 |
| 2017 | 14 | 61 | 2 | 9 |
| 2018 | 12 | 51 | 0 | 13 |
| 2019 | 18 | 60 | 0 | 10 |
| 2020 | 5 | 66 | 0 | 20 |
| 2021 | 5 | 266 | 0 | 41 |
| 2022 | 0 | — | 31 (9) | 11 |
| 2023 | 7 | 85 | 0 | 9 |
| 2024 | 6 | 90 | 0 | 1 |
| 2025 | 14 | 106 | 0 | 0 |
| 2026 | 2 | — | 0 | — |
What is it indicated for?
Etest® is a quantitative technique for determination of antimicrobial susceptibility of both non-fastidious Gram-negative and Gram-positive aerobic bacteria such as Enterobacteriaceae, Pseudomonas, Staphylococcus, and Enterococcus species and fastidious bacteria, such as anaerobes, N. gonorrhoeae, S. pneumoniae, Streptococcus and Haemophilus species. The system comprises a predefined antibiotic gradient which is used to determine the Minimum Inhibitory…
Read the full statement (159 words)
Etest® is a quantitative technique for determination of antimicrobial susceptibility of both non-fastidious Gram-negative
and Gram-positive aerobic bacteria such as Enterobacteriaceae, Pseudomonas, Staphylococcus, and Enterococcus species
and fastidious bacteria, such as anaerobes, N. gonorrhoeae, S. pneumoniae, Streptococcus and Haemophilus species. The
system comprises a predefined antibiotic gradient which is used to determine the Minimum Inhibitory Concentration
(MIC), in μg/mL, of different antimicrobial agents against microorganisms as tested on agar media using overnight
incubation.
Ceftazidime/Avibactam has been shown to be active against the Gram negative aerobic microorganisms listed below,
according to the FDA label for this antimicrobial agent.
Etest® CZA can be used to determine the MIC of Ceftazidime/Avibactam against the microorganisms listed below:
Active both in vitro and in clinical infections:
Citrobacter freundii
Enterobacter cloacae
Escherichia coli
Klebsiella oxytoca
Klebsiella pneumoniae
Proteus mirabilis
Pseudomonas aeruginosa
The following in vitro data are available, but clinical significance is unknown:
Citrobacter koseri
Enterobacter aerogenes
Morganella morganii
Providencia rettgeri
Providencia stuartii
Serratia marcescens
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K172150 · printed Nov 6, 2026
Cite this page
510(k) Report. “K172150: Etest Ceftazidime/Avibactam (CZA) (0.016 - 256 ug/mL).” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K172150
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026